IL-4 and IL-13 Drive Chronic Type-2 Skin Inflammation
Placeholder: excess IL-4/IL-13 signaling sustains atopic dermatitis flares.
- IL-4 / IL-13: Key cytokines (Placeholder short note)
- Th2 cell: Driven cell type (Placeholder short note)
- IL-4Rα: Shared receptor (Placeholder short note)
- Atopic dermatitis: Clinical context (Placeholder short note)
Cytokine overdrive in Th2 disease
Placeholder paragraph describing IL-4/IL-13 overactivity in short form.
Dupilumab Binds IL-4Rα to Block Two Cytokines at Once
Placeholder: one antibody target intercepts both type I and type II receptor complexes.
- mAb: Drug class (Placeholder short note)
- IL-4Rα: Target (Placeholder short note)
- Type I & II: Receptors blocked (Placeholder short note)
- Subcutaneous: Dosing (Placeholder short note)
Mechanism of dual-pathway blockade
Placeholder paragraph describing dupilumab receptor binding briefly.
Interrupting Cytokine Drive Quiets Pruritus Circuits
Placeholder: sensory neuron sensitization falls as signaling drops.
- Pruritus: Symptom (Placeholder short note)
- Days-weeks: Onset of relief (Placeholder short note)
- JAK-STAT6: Pathway (Placeholder short note)
- NRS itch scale: Patient metric (Placeholder short note)
Neuroimmune itch signaling drop
Placeholder paragraph describing itch pathway suppression briefly.
Skin Lesions Resolve Progressively Across Weeks
Placeholder: erythema and lichenification decline with sustained therapy.
- 0-16 wk: Timeframe (Placeholder short note)
- Barrier repair: Tissue effect (Placeholder short note)
- Erythema fade: Visible sign (Placeholder short note)
- IGA / EASI: Assessment tool (Placeholder short note)
Progressive lesion clearance
Placeholder paragraph describing skin clearance over time briefly.
EASI Score Decline Quantifies Clinical Response
Placeholder: EASI-50/75/90 thresholds classify treatment response.
- EASI: Score used (Placeholder short note)
- 50/75/90: Response tiers (Placeholder short note)
- Week 16: Trial benchmark (Placeholder short note)
- Sustained control: Outcome (Placeholder short note)
Reading the EASI response curve
Placeholder paragraph describing EASI curve interpretation briefly.
Placeholder highlight: strong responders reach EASI-75 by week sixteen.